Pleural mesothelioma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 18 Jun 2026 04:07:44 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pleural mesothelioma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment https://clinicaltrials.eu/trial/study-of-fianlimab-plus-cemiplimab-with-chemotherapy-or-cemiplimab-with-chemotherapy-for-patients-with-pleural-mesothelioma-who-have-not-received-prior-treatment/ Thu, 30 Apr 2026 13:08:21 +0000 https://clinicaltrials.eu/trial/study-of-fianlimab-plus-cemiplimab-with-chemotherapy-or-cemiplimab-with-chemotherapy-for-patients-with-pleural-mesothelioma-who-have-not-received-prior-treatment/ This study is looking at a type of cancer called pleural mesothelioma, which affects the lining of the lungs. The study will test two different treatment combinations. One combination includes fianlimab (also known as REGN3767), cemiplimab (also known as LIBTAYO), and chemotherapy with pemetrexed and platinum. The other combination includes cemiplimab and chemotherapy with pemetrexed and platinum. Both fianlimab and cemiplimab are medicines that work with the immune system to help fight cancer. The chemotherapy medicines are drugs that work to kill or slow the growth of cancer cells.

The purpose of this study is to see how well the combination of double immunotherapy with anti-LAG3 and anti-PD-1 medicines along with chemotherapy works in treating this disease. The study will look at how many patients have their disease controlled after six months of treatment. Patients in this study will not have received any previous chemotherapy or immunotherapy for their pleural mesothelioma. The study will also look at how safe these treatment combinations are and what side effects patients may experience. The treatments will be given through an intravenous infusion, which means the medicine is delivered directly into a vein.

During the study, doctors will check how well the treatments are working by using scans and measurements to see if the tumors are getting smaller, staying the same, or growing. The study will also look at how the treatments affect patients’ quality of life and symptoms. Patients will be followed to see how long they live and how long they go without their disease getting worse. The study will compare results between patients who have different types of pleural mesothelioma, specifically the epithelioid type versus the non-epithelioid type. Treatment in this study can last up to 24 months.

]]> Study on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab https://clinicaltrials.eu/trial/study-on-safe-skin-test-concentrations-for-biotherapy-allergies-in-patients-with-cancer-using-atezolizumab-daratumumab-and-nivolumab/ Wed, 29 Apr 2026 15:05:16 +0000 https://clinicaltrials.eu/trial/study-on-safe-skin-test-concentrations-for-biotherapy-allergies-in-patients-with-cancer-using-atezolizumab-daratumumab-and-nivolumab/ This clinical trial is focused on evaluating skin tests for allergies related to certain biotherapy treatments. The diseases being studied include Chronic Lymphocytic Leukemia, AL Amyloidosis, Esophageal Squamous Cell Carcinoma, Myeloma, Cholangiocarcinoma, Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Colorectal Adenocarcinoma with deficient mismatch repair, Small Cell Lung Carcinoma, Follicular Lymphoma, Melanoma, Hepatocellular Carcinoma, Gastric Cardia Cancer, Locally Advanced Cutaneous Squamous Cell Carcinoma, and Pleural Mesothelioma. The treatments being tested include Atezolizumab, Nivolumab, Obinutuzumab, Durvalumab, Pembrolizumab, Daratumumab, and Cemiplimab. These treatments are types of biotherapy, which use substances made from living organisms to treat diseases.

The purpose of the study is to find out the highest concentration of these biotherapy drugs that can be used in skin tests without causing irritation in patients who are not allergic. The study will involve skin tests, such as prick tests and intradermal tests, to check for any allergic reactions. Patients who have been treated with these biotherapies and have not shown any allergic reactions will be part of the study. The study will monitor for any immediate or delayed skin reactions after the tests.

Throughout the study, patients will be contacted to confirm if there are any delayed reactions, which might occur up to a week after the skin tests. If a reaction is suspected, a photograph or video consultation with an allergist may be used to confirm it. The study aims to ensure that the skin tests are safe and do not cause unnecessary irritation to patients undergoing biotherapy treatments.

]]> Study of Niraparib and Dostarlimab for Patients with Advanced Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma with Specific Genetic Mutations https://clinicaltrials.eu/trial/study-of-niraparib-and-dostarlimab-for-patients-with-advanced-non-small-cell-lung-cancer-or-malignant-pleural-mesothelioma-with-specific-genetic-mutations/ Wed, 29 Apr 2026 15:02:17 +0000 https://clinicaltrials.eu/trial/study-of-niraparib-and-dostarlimab-for-patients-with-advanced-non-small-cell-lung-cancer-or-malignant-pleural-mesothelioma-with-specific-genetic-mutations/ This clinical trial is focused on studying two types of cancer: non-small cell lung cancer and pleural mesothelioma. These are serious conditions where cancer cells form in the tissues of the lung or the lining of the chest. The study is testing a combination of two medications, niraparib and dostarlimab. Niraparib is taken as a capsule, while dostarlimab is given through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein.

The purpose of the study is to see how well this combination of medications works in patients who have these cancers and specific genetic features, such as being positive for PD-L1 expression and having mutations in the HRR genes. PD-L1 is a protein that can affect the immune system’s ability to fight cancer, and HRR genes are involved in repairing DNA. The study will follow participants over a period of up to 24 months to observe the effects of the treatment.

Participants in the study will receive the medications and be monitored regularly to assess their health and the progression of their cancer. The study aims to understand how long patients can live without their cancer getting worse, how their cancer responds to the treatment, and the overall safety of using niraparib and dostarlimab together. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. The study will help determine if this combination of medications can be a beneficial treatment option for these types of cancer.

]]> Study on the Use of 68Ga-FAPI-46 and Fludeoxyglucose (18F) for Diagnosing Pleural Mesothelioma in Patients https://clinicaltrials.eu/trial/study-on-the-use-of-68ga-fapi-46-and-fludeoxyglucose-18f-for-diagnosing-pleural-mesothelioma-in-patients/ Wed, 29 Apr 2026 14:58:35 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-68ga-fapi-46-and-fludeoxyglucose-18f-for-diagnosing-pleural-mesothelioma-in-patients/ This clinical trial is focused on studying a disease called pleural mesothelioma, which is a type of cancer that affects the lining of the lungs. The study will use a special imaging technique called FAPI PET to see how well it can detect and evaluate this cancer. FAPI PET involves using a substance called 68Ga-FAPI-46, which is injected into the body and helps to highlight cancer cells during imaging. This study will also compare FAPI PET with another imaging method called FDG PET, which uses a substance known as Fluor-18-FDG.

The purpose of the study is to see how accurate FAPI PET is in diagnosing and staging pleural mesothelioma. Participants will undergo imaging with both FAPI PET and FDG PET to compare the results. The study will look at how these imaging techniques can help in planning treatment and assessing how well the treatment is working. The study will also explore if FAPI PET can provide more detailed information about the cancer compared to traditional imaging methods.

Throughout the study, participants will receive injections of the imaging substances and undergo scans to capture images of the cancer. The study will track changes in the cancer over time, especially after a few rounds of cancer treatment. The results from FAPI PET will be compared to those from FDG PET to determine which method provides better information for managing pleural mesothelioma. The study aims to improve understanding of how these imaging techniques can be used to guide treatment decisions and improve outcomes for patients with this type of cancer.

]]> Study of Volrustomig with Carboplatin and Pemetrexed for Patients with Unresectable Pleural Mesothelioma https://clinicaltrials.eu/trial/study-of-volrustomig-with-carboplatin-and-pemetrexed-for-patients-with-unresectable-pleural-mesothelioma/ Wed, 29 Apr 2026 14:25:46 +0000 https://clinicaltrials.eu/trial/study-of-volrustomig-with-carboplatin-and-pemetrexed-for-patients-with-unresectable-pleural-mesothelioma/ This clinical trial is focused on studying a disease called unresectable pleural mesothelioma, which is a type of cancer that affects the lining of the lungs and cannot be removed through surgery. The study is testing a new treatment option that combines a medication called volrustomig (also known by its code name MEDI5752) with two other drugs, carboplatin and pemetrexed. These medications are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. The trial will compare this new combination treatment to other standard treatments, which include either a combination of nivolumab and ipilimumab or a combination of platinum-based drugs with pemetrexed.

The purpose of the study is to determine if the new treatment combination is more effective in improving the overall survival of patients with pleural mesothelioma compared to the standard treatments. Participants in the study will receive one of the treatment options and will be monitored over time to assess their response to the treatment and any side effects they may experience. The study will also look at other factors such as how long the treatment works, the time it takes for the disease to progress, and the overall response rate to the treatment.

Throughout the study, participants will undergo regular check-ups, which may include physical exams, blood tests, and other assessments to monitor their health and the effects of the treatment. The trial aims to provide valuable information that could lead to better treatment options for people with pleural mesothelioma in the future.

]]>